Reviva Pharmaceuticals Holdings, Inc. Interest Expense
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Interest Expense of $3.49 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-14
- Reviva Pharmaceuticals Holdings, Inc. interest expense for the quarter ending 2024-03-31 was $3.49K, a 54.45% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. interest expense for the quarter ending 2023-09-30 was $5.90K.
- Reviva Pharmaceuticals Holdings, Inc. interest expense for the quarter ending 2023-06-30 was $12.76K.
- Reviva Pharmaceuticals Holdings, Inc. interest expense for the quarter ending 2023-03-31 was $7.66K.
- Reviva Pharmaceuticals Holdings, Inc. interest expense for fiscal 2020 was $1.45M, a 209.59% increase from fiscal 2019.
- Reviva Pharmaceuticals Holdings, Inc. interest expense for fiscal 2019 was $469.37K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 11 month | Interest Expense 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $3.49K 10-Q · filed 2024-05-14 | ||||
| 2023-09-30 | $5.90K 10-Q · filed 2023-11-14 | $18.66K derived: sum of 2 quarters · filed 2023-11-14 | $20.41K 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $12.76K 10-Q · filed 2023-08-14 | $20.41K 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $7.66K 10-Q · filed 2024-05-14 | ||||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | ||||
| 2021-12-13 | $0.00 10-K · filed 2022-03-15 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-16 | $0.00 10-Q · filed 2021-08-16 | |||
| 2020-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $1.22M derived: sum of 2 quarters · filed 2022-03-15 | $1.32M derived: sum of 3 quarters · filed 2022-03-15 | $1.45M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $146.25K 10-Q · filed 2021-11-15 | $245.30K derived: sum of 2 quarters · filed 2021-11-15 | $375.19K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $99.05K 10-Q · filed 2021-08-16 | $228.94K 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | $129.88K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | $469.37K 10-K/A · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |